Your session is about to expire
What is Rubraca
RucaparibThe Generic name of this drug
Treatment SummaryRucaparib is a medication used to treat advanced ovarian cancer. It is a type of drug called a poly (ADP-ribose) polymerase (PARP) inhibitor, which works by blocking an enzyme that helps cancer cells repair their DNA. Rucaparib is approved to treat ovarian cancers with BRCA1 or BRCA2 genetic mutations, or tumors with high levels of homologous recombination deficiency (HRD) loss of heterozygosity (LOH). It is marketed in the US under the brand name Rubraca.
Rubracais the brand name
Rubraca Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Rubraca
Rucaparib
2016
3
Effectiveness
How Rubraca Affects PatientsRucaparib is a medication used to treat cancer. It works by blocking an enzyme called poly (ADP-ribose) polymerase (PARP) that helps cancer cells repair their DNA. Rucaparib has been found to prevent tumour growth and when combined with other chemotherapy drugs, it can increase the effectiveness of treatment. Additionally, it can cause blood vessels to widen, which can help chemotherapy drugs get to the cancer cells more effectively.
How Rubraca works in the bodyRucaparib is a drug designed to fight cancer cells with a genetic defect called BRCA mutation. This mutation prevents the cells from using the normal process for repairing their DNA. Rucaparib blocks three proteins – PARP1, PARP2, and PARP3 – which are normally used in DNA repair. This traps the proteins on damaged DNA and prevents them from repairing it. The cell is then left with toxic DNA that can't be repaired and eventually leads to its death. In BRCA-deficient cells, this process is called synthetic lethality, where two non-lethal defects combine and cause
When to interrupt dosage
The measure of Rubraca is contingent upon the diagnosed condition. The quantity of dosage can be observed in the table below, contingent upon the method of administration.Condition
Dosage
Administration
maintenance therapy
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Fallopian Tube Reanastomosis
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Pharmacotherapy
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Castration
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Recurrent Primary Peritoneal Cancer
, 200.0 mg, 300.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral
Warnings
Rubraca ContraindicationsCondition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Rucaparib may interact with Pulse Frequency
Common Rubraca Drug Interactions
Drug Name
Risk Level
Description
Eliglustat
Major
The metabolism of Eliglustat can be decreased when combined with Rucaparib.
Fentanyl
Major
The metabolism of Fentanyl can be decreased when combined with Rucaparib.
Ozanimod
Major
Rucaparib may decrease the excretion rate of Ozanimod which could result in a higher serum level.
Rimegepant
Major
The serum concentration of Rimegepant can be increased when it is combined with Rucaparib.
9-aminocamptothecin
Minor
The metabolism of 9-aminocamptothecin can be decreased when combined with Rucaparib.
Rubraca Toxicity & Overdose RiskThe toxic dose and effects of overdosing on rucaparib are currently unknown.
Rubraca Novel Uses: Which Conditions Have a Clinical Trial Featuring Rubraca?
Twelve active studies are assessing the potential of Rubraca to treat Advanced Ovarian Cancer.Condition
Clinical Trials
Trial Phases
Recurrent Primary Peritoneal Cancer
1 Actively Recruiting
Phase 1, Phase 2
maintenance therapy
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Castration
28 Actively Recruiting
Phase 1, Phase 2, Phase 3
Fallopian Tube Reanastomosis
0 Actively Recruiting
Rubraca Reviews: What are patients saying about Rubraca?
2.7Patient Review
9/10/2020 Despite lowering my dosage twice, I'm still experiencing extreme fatigue, very little motivation, shortness of breath and dizziness.
Patient Q&A Section about rubraca
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How long can you take Rubraca?
"Rucaparib is typically taken 2 months after the last dose of platinum chemotherapy. Treatment with rucaparib is continued as long as the drug is effective and the side effects are tolerable."
Answered by AI
Is Rubraca a chemo pill?
"The prescription medicine Rubraca is used in adults to treat ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has returned and is responding to platinum-based chemotherapy."
Answered by AI
Can Rubraca cure cancer?
"While Rubraca is not officially approved to treat pancreatic cancer by the FDA, some doctors may prescribe it for this purpose based on Clinical studies which have shown the drug to be effecting treating pancreatic cancer in adults with BRCA genetic mutations who had received at two chemotherapy drugs previously."
Answered by AI
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.